1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Seagen Inc.
  6. News
  7. Summary
    SGEN   US81181C1045

SEAGEN INC.

(SGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Seagen Inc. Announces Data from Phase I Clinical Trial Combining SEA-CD40

01/18/2022 | 05:00pm EDT

Seagen Inc. announced data from a phase 1 clinical trial combining SEA-CD40 with chemotherapy and an anti-PD-1 in patients with metastatic PDAC at the ASCO GI annual meeting taking place in San Francisco, January 20 – 22, 2022. SEA-CD40 is a novel, investigational, nonfucosylated monoclonal receptor-agonistic antibody directed to CD40, which is expressed on antigen-presenting cells. In preclinical models, the combination of SEA-CD40 and chemotherapy resulted in antitumor activity which is further enhanced with anti-PD-1 treatment. In the ongoing phase 1 trial, SEA-CD40 was combined with chemotherapy [gemcitabine and nab-paclitaxel (GnP)], and an anti-PD-1 (pembrolizumab), in 61 patients with untreated metastatic PDAC. Of these, 40 patients received 10 mcg/kg and 21 patients received 30 mcg/kg of SEA-CD40. Key endpoints include confirmed objective response rate (cORR) per RECIST v1.1 by investigator, progression-free survival (PFS) and overall survival (OS). Activity of SEA-CD40 in combination with GnP and pembrolizumab was observed in both doses of SEA-CD40 tested. The overall (N = 61) cORR was 44 percent, median PFS was 7.4 months (95% CI: 5.6-9.0), and median OS was 15.0 months (95 percent CI: 7.8-19.9). Follow-up for efficacy is ongoing. The regimen demonstrated a manageable and tolerable safety profile. Overall, = grade 3 treatment-emergent adverse events (TEAEs) were fatigue, nausea, neutropenia, infusion-related reaction, chills, diarrhea, and pyrexia. This combination also showed evidence of immune activation consistent with the SEA-CD40 mechanism of action.


ę S&P Capital IQ 2022
All news about SEAGEN INC.
05/27INSIDER SELL : Seagen
MT
05/26Takeda Pharmaceutical Company Limited and Seagen Inc. to Highlight ADCETRIS« Combinatio..
CI
05/23Seagen Sees Positive Topline Data From Study of Tukysa With Trastuzumab in HER2-Positiv..
MT
05/23SEAGEN : Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA« (..
PU
05/23SEAGEN INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/23Seagen Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA« ..
BU
05/23Seagen Inc. Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUK..
CI
05/23SEAGEN INC. : SEC Filing 8K
CO
05/19SEAGEN INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/16US Stocks Begin Week Mostly Lower Amid Empire State Manufacturing Weakness
MT
More news
Analyst Recommendations on SEAGEN INC.
More recommendations
Financials (USD)
Sales 2022 1 793 M - -
Net income 2022 -651 M - -
Net cash 2022 1 615 M - -
P/E ratio 2022 -39,9x
Yield 2022 -
Capitalization 26 026 M 26 026 M -
EV / Sales 2022 13,6x
EV / Sales 2023 9,62x
Nbr of Employees 2 675
Free-Float 99,2%
Chart SEAGEN INC.
Duration : Period :
Seagen Inc. Technical Analysis Chart | SGEN | US81181C1045 | MarketScreener
Technical analysis trends SEAGEN INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 141,39 $
Average target price 160,94 $
Spread / Average Target 13,8%
EPS Revisions
Managers and Directors
Roger D. Dansey Chief Executive & Medical Officer
Todd E. Simpson Chief Financial Officer
Felix James Baker Chairman
Vaughn B. Himes Chief Technical Officer
David W. Gryska Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SEAGEN INC.-8.54%26 026
MODERNA, INC.-41.86%58 733
LONZA GROUP AG-24.79%44 437
IQVIA HOLDINGS INC.-21.85%41 736
ICON PUBLIC LIMITED COMPANY-26.61%18 478
CELLTRION, INC.-21.21%17 245